Other substances

L-Carnitine

An amino acid derivative.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Natural product

1
 Supporting references
0
 Contradictory references
4
 AI-suggested references
1
 Clinical trials

General information

L-carnitine is an amino acid derivative which facilitates long-chain fatty acid entry into mitochondria. Fatty acids are thus used as an energy substrate in most of human tissues (NCIt).

L-Carnitine on PubChem
L-Carnitine on DrugBank
L-Carnitine on Wikipedia

Synonyms

Levocarnitine; (R)-Carnitine; (-)-Carnitine; Karnitin

 

C[N+](C)(C)C[C@@H](CC(=O)[O-])O

Supporting references

Link Tested on Impact factor Notes Publication date
L-Carnitine Tartrate Downregulates the ACE2 Receptor and Limits SARS-CoV-2 Infection
Small molecule In vitro 		Vero E6 cells; Calu-3 cells; SARS-CoV-2 isolate LSPQ1; rats and healthy humans (host dependency factors levels’ assessment only) 5.72

In the form of CarnipureTM tartrate. Decreased ACE2, TMPRSS2 and Furin levels in rodent and human tissues following exercise-induced inflammation. The preparation decreased susceptibility of Calu-3 cells to SARS-CoV-2 infection.

 Apr/14/2021

AI-suggested references

Link Publication date
A Pilot, Phase II, Observational, Case-Control, 1-Month Study on Asthenopia in Video Terminal Operators without Dry Eye: Contrast Sensitivity and Quality of Life before and after the Oral Consumption of a Fixed Combination of Zinc, L-Carnitine, Extract of
Jun/16/2021
Delta9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.
Aug/28/2020
The effects of l-carnitine supplementation on inflammatory factors, oxidative stress, and clinical outcomes in patients with sepsis admitted to the intensive care unit (ICU): study protocol for a double blind, randomized, placebo-controlled clinical trial
Apr/06/2022
Clinical Study on the Efficacy and Safety of Arginine Administered Orally in Association with Other Active Ingredients for the Prevention and Treatment of Sarcopenia in Patients with COVID-19-Related Pneumonia, Hospitalized in a Sub-Intensive Care Unit
May/21/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04623619 Efficacy and Safety of Acetyl L-Carnitine in COVID-19 Patients With Mild-to-Moderate Disease Not yet recruiting Not Applicable Dec/15/2020 Jul/31/2021
  • Alternative id - 20201109
  • Interventions - Dietary Supplement: Acetyl L-Carnitine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - In-hospital mortality|C reactive protein (CRP) levels|IL-6 levels|D-dimer levels|Hospital stay|Duration of positive PCR swab
Export (.csv)